^
    21h
    Shortened Course Adjuvant Radiotherapy Following TORS (clinicaltrials.gov)
    P2, N=104, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    24h
    OPSCC: Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=37, Terminated, M.D. Anderson Cancer Center | Active, not recruiting --> Terminated; <75% participation
    Trial termination • Tumor mutational burden
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    1d
    KEYNOTE 689: Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) (clinicaltrials.gov)
    P3, N=714, Active, not recruiting, Merck Sharp & Dohme LLC | N=175 --> 714
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin
    1d
    KEYNOTE-E72: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=51, Recruiting, Nykode Therapeutics ASA | N=78 --> 51
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • abipapogene suvaplasmid (VB10.16)
    1d
    BeeHive: A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P2, N=30, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting | Trial completion date: Jun 2030 --> Mar 2031
    Enrollment open • Trial completion date • IO biomarker
    |
    Jemperli (dostarlimab-gxly) • risvutatug rezetecan (GSK5764227)
    1d
    Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=403, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • fluorouracil topical
    2d
    Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer (clinicaltrials.gov)
    P2, N=180, Recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2026 --> Apr 2026
    Trial initiation date
    |
    cisplatin • carboplatin • paclitaxel • Libtayo (cemiplimab-rwlc)
    2d
    Clinical Significance of Biomarkers in Oropharyngeal Squamous Cell Carcinoma: Recurrence Prediction and Treatment Response. (PubMed, Cancer Rep (Hoboken))
    While several biomarkers show promise in OPSCC, further standardization of detection methods and large-scale prospective studies are required. Integration of multi-omics data with computational approaches, including artificial intelligence, may facilitate the development of robust and clinically actionable predictive models, ultimately enabling more personalized management and earlier detection of recurrence.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    3d
    RAIN-HNSCC: Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Chen Chunyan
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    AiRuiLi (adebrelimab)
    7d
    TARGET-HPV: TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers (clinicaltrials.gov)
    P1/2, N=35, Active, not recruiting, University of Chicago | N=98 --> 35 | Not yet recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    carboplatin • paclitaxel
    7d
    Inhibitory role of angiopoietin‑like 4 for cancer progression in oropharyngeal squamous cell carcinoma. (PubMed, Oncol Rep)
    Thus, ANGPTL4 may serve as a prognostic biomarker in OPSCC. Further in vivo studies are warranted to clarify causality and assess the therapeutic potential of ANGPTL4 targeting in OPSCC.
    Retrospective data • Journal
    |
    ANGPTL4 (Angiopoietin Like 4)
    8d
    A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (clinicaltrials.gov)
    P2, N=121, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • albumin-bound paclitaxel